2022-12-19-世界卫生组织-6._Influenza_B_Yamagata_Lineage_-_Cell_culture-derived_-_Southern_Hemisphere_2023_2页_189kb

Influenza B Yamagata lineage vaccines for the 2023 southern hemisphere season are developed using cell culture-derived candidate vaccine viruses (ccCVVs) or recombinant antigens. WHO Collaborating Centers isolate and analyze these viruses from certified cell lines, such as MDCK, ensuring they pass two-way hemagglutination inhibition (HI) tests against prototype viruses. Recombinant antigens must closely match the sequence of B/Phuket/3073/2013. National or regional control authorities approve vaccine formulation and manufacturing. The text provides details on specific viruses, institutes like VIDRL, and contact information for orders.

Key points:

• WHO role in isolation and analysis.
• Approval process by control authorities.
• Recombinant antigen requirements.
• Contact details for reagents and inquiries.